Menu

We live in a golden age of medical science.

But over two billion people can’t access the medicines they need, causing preventable illness, disease and death.

We’re here to change that.

Bridging the gap between makers and buyers

MedAccess is a social enterprise committed to improving health in low- and middle-income countries.

We broker partnerships that remove barriers stopping lifesaving medical innovations reaching people who need them.

Our agreements with makers and buyers across the health ecosystem speed up access to healthcare. We shoulder financial risk to strengthen health markets, enabling more products to reach more people more quickly.

What we do

We accelerate access to lifesaving products

Advances in medical science mean that many illnesses that would have been fatal just a few years ago can now be prevented, treated and cured.

But for millions of people around the world, these advances are either unavailable or unaffordable.

Unequal access to medical innovation leads to millions of preventable deaths every year. Too often, the people with the least resources are forced to wait years, or even decades, for the health products they need.

We believe people should have access to effective medical innovations when they need them, no matter where they live.

Access to healthcare: a daily emergency

Putting everyone on a more equal footing

We are helping to make vaccines, diagnostics, treatments and other health technologies more affordable and available for people in low- and middle-income countries.

To date, our agreements have enabled medical innovations to reach 530 million people in over 95 countries.

By securing lower prices for products, we are helping procurers to save money, which can be used to tackle other urgent health needs.

Our impact

Because fair access is at the heart of a healthier future

Since our foundation in 2017, we have secured nine agreements to increase access to health products. Our agreements are helping to tackle HIV, tuberculosis, malaria, syphilis and COVID-19.

All our agreements support strong partnerships that include businesses, global health organisations, countries, and civil society. We strongly believe that partnership is at the heart of transformational and sustainable health impact.

We are also aiming to expand our work to tackle non-communicable diseases, such as cancer and diabetes. We believe we can make a significant impact on the growing burden of non-communicable diseases in low- and middle-income countries, helping millions more people to live longer, healthier lives.

Our agreements

Our funders

MedAccess was founded by British International Investment (BII), the UK’s development finance institution. BII is our anchor investor, with $200 million paid-in capital.

Since 2021, the UK’s Foreign, Commonwealth & Development Office (FCDO) has provided us with £17 million in grant funding as part of its Global Fund Accelerator grants.

Support our work
BII logo

British International Investment

FCDO logo

Foreign, Commonwealth & Development Office

How do advance market commitments and volume guarantees shape healthcare markets?

In an ideal world, markets function perfectly. Buyers and sellers trade goods and services. Production and consumption are efficient.

In reality, market failures and inefficiencies exist. The impact of these market failures is stark in healthcare, compromising public health outcomes and increasing patient morbidity and mortality.

Market-shaping interventions such as advance market commitments and volume guarantees can enable healthcare markets to function more efficiently.

Learn more

Latest news

Find out more about our partnerships by reading our press releases, news stories and insight articles.

Latest news

MedAccess welcomes rollout of G6PD testing and tafenoquine in Brazil

MedAccess today welcomed news from Brazil that people from the Yanomami Indigenous Territory in Roraima will become the first to benefit from the country’s national rollout of point-of-care glucose-6-phosphate-dehydrogenase (G6PD) testing and single-dose tafenoquine to tackle P. vivax malaria. Brazil is the first malaria-endemic country in the world to adopt this new treatment. Last week, 105 health representatives from the…

A nurse takes the blood pressure of a pregnant woman. The words 'Access Matters' overlay the image.

Subscribe to our newsletter

Receive regular updates about how our innovative finance work is making healthcare products more affordable and accessible.

Close